Skip to main content
RGNT logo

Regentis Biomaterials Ltd.

RGNTNYSEAMERICANHealthcareMedical Instruments & Supplies

$1.49Today:- (-)

As of Oct 16, 2026 close

Market cap
$9.23M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.23$15.50
Volume (live)
-
Avg. volume (3M)
54.67K

Regentis Biomaterials (RGNT) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Regentis Biomaterials used $1.38M of cash in operating activities. Free cash flow was −$1.38M.

Regentis Biomaterials Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Regentis Biomaterials Ltd. (RGNT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-13.654.80-4.13-1.45-5.14-0.41
Stock Based Compensation7.04-----
Change in Working Capital0.13-1.600.71-0.120.85-0.27
Change in Accounts Payable0.01-0.100.25-0.101.22-0.09
Change in Other Working Capital-0.16-0.242.19-0.114.46-0.18
Other Operating Activities5.10-3.842.190.074.460.14
Net Cash from Operating Activities-1.38-0.64-1.22-1.500.13-0.54
Investing Activities
Net Cash from Investing Activities------
Financing Activities
Debt Repayment--0.33----
Common Stock Issued8.22-----
Net Cash from Financing Activities8.520.530.33-1.240.50
Summary
Net Change in Cash7.15-0.12-0.90-1.501.37-0.04
Cash at Beginning of Period0.230.351.242.741.38-
Cash at End of Period7.380.230.351.242.74-
Free Cash Flow-1.38-0.64-1.22-1.500.13-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Regentis Biomaterials Cash Flow

What is Regentis Biomaterials's free cash flow?

Regentis Biomaterials had negative free cash flow of $1.38M in fiscal 2025 (fiscal year ended Dec 31, 2025).

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition